ArticleVeterinary medicine and science2026
Oral Antioxidant Provides Adjunctive Therapeutic Benefits Alongside Dexamethasone in a Rat Model of Endotoxin-Induced Uveitis.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundSeveral antioxidant combinations are commercially available; however, it remains unclear whether these combinations can enhance the anti-inflammatory effects of systemic corticosteroids in acute uveitis models.
objectivesTo evaluate the anti-inflammatory and antioxidant effects of an orally administered antioxidant formulation in a lipopolysaccharide-induced uveitis rat model and explore its potential as an adjunctive therapy to corticosteroid treatment.
methodsSeventy-five male Sprague-Dawley rats were randomly and evenly assigned to five groups and orally treated for 10 days with antioxidant formulations, either alone or in combination with intravenous dexamethasone. Uveitis was induced via subcutaneous lipopolysaccharide injection. Clinical severity was assessed using a slit-lamp biomicroscope. Subsequently, a subset of five randomly selected rats per group underwent biochemical analyses of the aqueous humour and histopathological evaluation of the ocular tissues.
resultsThe lipopolysaccharide-treated group exhibited the highest clinical score, which was significantly reduced by dexamethasone monotherapy and combination treatment. Moreover, the antioxidant formulation significantly reduced inflammatory cell infiltration in the aqueous humour, which was further diminished by the combination treatment. TNF-α and IL-6 levels decreased upon combination therapy, yielding significantly lower TNF-α levels than those with dexamethasone monotherapy. Combination treatment significantly increased IL-10 levels. Moreover, total superoxide dismutase activity was highest in the combination group. No significant differences were observed in the histopathological scores or total protein concentrations between the dexamethasone and combination groups.
conclusionsCo-administration of dexamethasone and an antioxidant is a potential adjunctive therapeutic strategy for mitigating oxidative tissue damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.